Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Hau

Showing results (141-150 of 180) with videos related to

Pageof 18
Sort By:
International Journal of Cancer|October 28, 2020
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trialTheophilos Tzaridis, Niklas Schäfer, Johannes Weller, et al.
The Lancet. Oncology|September 7, 2019
Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trialJohannes Weller, Theophilos Tzaridis, Frederic Mack, et al.
Journal of Neuro-Oncology|September 20, 2023
Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analysesThomas Zeyen, Daniel Paech, Johannes Weller, et al.
The Lancet. Haematology|August 2, 2016
High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trialGerald Illerhaus, Benjamin Kasenda, Gabriele Ihorst, et al.
Oligonucleotides|July 20, 2007
Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studiesPeter Hau, Piotr Jachimczak, Reimar Schlingensiepen, et al.
Journal of Neuro-Oncology|November 3, 2023
Correction to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analysesThomas Zeyen, Daniel Paech, Johannes Weller, et al.
Journal of Neuro-Oncology|May 6, 2020
Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 studyLinda Dirven, Ralf Luerding, Dagmar Beier, et al.
Neuro-Oncology Advances|October 26, 2022
First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed <i>MGMT</i> promoter methylated <i>IDH</i> wildtype glioblastomaLazaros Lazaridis, Elisabeth Bumes, Dorothee Cäcilia Spille, et al.
Journal of Cancer Research and Clinical Oncology|May 30, 2018
Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trialChristina Schaub, Sied Kebir, Nina Junold, et al.
Cancer Medicine|April 22, 2025
Temporal Muscle Thickness as a Prognostic Marker in a Real-Life Cohort of Newly Diagnosed MGMT Promoter Methylated Glioblastoma: A Multicentric Imaging AnalysisLazaros Lazaridis, Christoph Moenninghoff, Elisabeth Bumes, et al.
Pageof 18

Showing results (141-150 of 180) with videos related to

Sort By:
Pageof 18
International Journal of Cancer|October 28, 2020
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trialTheophilos Tzaridis, Niklas Schäfer, Johannes Weller, et al.
The Lancet. Oncology|September 7, 2019
Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trialJohannes Weller, Theophilos Tzaridis, Frederic Mack, et al.
Journal of Neuro-Oncology|September 20, 2023
Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analysesThomas Zeyen, Daniel Paech, Johannes Weller, et al.
The Lancet. Haematology|August 2, 2016
High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trialGerald Illerhaus, Benjamin Kasenda, Gabriele Ihorst, et al.
Oligonucleotides|July 20, 2007
Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studiesPeter Hau, Piotr Jachimczak, Reimar Schlingensiepen, et al.
Journal of Neuro-Oncology|November 3, 2023
Correction to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analysesThomas Zeyen, Daniel Paech, Johannes Weller, et al.
Journal of Neuro-Oncology|May 6, 2020
Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 studyLinda Dirven, Ralf Luerding, Dagmar Beier, et al.
Neuro-Oncology Advances|October 26, 2022
First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed <i>MGMT</i> promoter methylated <i>IDH</i> wildtype glioblastomaLazaros Lazaridis, Elisabeth Bumes, Dorothee Cäcilia Spille, et al.
Journal of Cancer Research and Clinical Oncology|May 30, 2018
Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trialChristina Schaub, Sied Kebir, Nina Junold, et al.
Cancer Medicine|April 22, 2025
Temporal Muscle Thickness as a Prognostic Marker in a Real-Life Cohort of Newly Diagnosed MGMT Promoter Methylated Glioblastoma: A Multicentric Imaging AnalysisLazaros Lazaridis, Christoph Moenninghoff, Elisabeth Bumes, et al.
Pageof 18